ArticleFrontiers in immunology2026
Integrating multi-omics and machine learning to unravel mechanisms of lymph node metastasis in papillary carcinoma with and without thyroiditis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, with lymph node metastasis (LNM) significantly influencing prognosis. PTC cases were categorized based on the presence or absence of coexisting thyroiditis: those with thyroiditis were designated as PTC-thyroiditis, and those without as PTC-blank. Although both subtypes exhibit distinct clinical and genomic profiles, the mechanisms underlying LNM-particularly the role of extracellular matrix (ECM) remodeling and cancer-associated fibroblasts (CAFs)-remain poorly understood. This study aimed to compare the molecular and cellular heterogeneity of PTC-blank and PTC-thyroiditis, identify key drivers of LNM, and develop a predictive model for clinical use. Methods: We integrated bulk RNA-seq data from the TCGA database and single-cell RNA-seq (scRNA-seq) data from GSE184362 to analyze clinical, genomic, and tumor microenvironment (TME) differences between PTC-blank and PTC-thyroiditis. Differential expression analysis, Gene Set Enrichment Analysis (GSEA), and immune cell infiltration analysis were performed. Fibroblast subpopulations were characterized at single-cell resolution. Machine learning algorithms (LASSO, random forest, KNN) were applied to identify LNM-related genes and construct a predictive model. Mendelian randomization (MR) and molecular docking were used to validate causal genes and potential drug interactions. Results: PTC-blank exhibited higher T, N, and M stages and increased mutations in BRAF and MUC16 compared to PTC-thyroiditis. LNM in PTC-blank was associated with ECM remodeling and collagen fiber accumulation, associated with a distinct PI16+ fibroblast subcluster with active ECM organization functions. In contrast, LNM in PTC-thyroiditis involved immune-related pathways without significant fibroblast infiltration or ECM changes. A 17-gene predictive model for LNM was developed, with the KNN classifier demonstrating high accuracy. MR analysis identified SHISA5 as a causal risk gene for thyroid cancer, and molecular docking revealed strong binding affinity with acetaminophen, suggesting therapeutic potential. Conclusions: PTC-blank and PTC-thyroiditis exhibit distinct LNM mechanisms: ECM remodeling and fibroblast infiltration are associated with metastasis in PTC-blank, while immune dysregulation appears to be more prominent in PTC-thyroiditis. The identified 17-gene model offers robust predictive value for LNM risk, and SHISA5 represents a novel causal gene and potential therapeutic target. These findings provide insights into subtype-specific management strategies for PTC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.